EVENTS · NAMS
PEERS
EARNINGS
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on developing oral therapies for cardiometabolic diseases, especially patients whose current lipid-lowering treatments are not adequately effective or well tolerated. The company’s lead program centers on obicetrapib, a low-dose oral CETP inhibitor being studied as a monotherapy and in combination with ezetimibe to help lower LDL cholesterol in cardiovascular settings. NewAmsterdam Pharma also works on broader applications for cardiometabolic care, reflecting its emphasis on non-statin medicine and patient-friendly treatment options. Headquartered in Naarden, the Netherlands, NewAmsterdam Pharma Company N.V. serves the biotechnology and pharmaceuticals market by advancing drug candidates aimed at addressing unmet needs in long-term cardiovascular risk management.
NewAmsterdam Pharma Receives European Commission Approval for Ubeslo and Evlarco
| Series | 1W | 1M |
|---|---|---|
| NAMS | −0.7% | −6.0% |
| Peers | +1.6% | +5.3% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 26 | 18 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q2 FY2026 | −0.50 | −0.52 | −4.44% | — |
| Q1 FY2026 | −0.50 | −0.40 | +20.32% | +24.98% |
| Q4 FY2025 | −0.39 | −0.62 | −57.84% | −1.73% |
| Q3 FY2025 | −0.40 | −0.61 | −50.95% | +1.42% |
| Series | 1W | 1M |
|---|---|---|
| NAMS | −0.7% | −6.0% |
| Peers | +1.6% | +5.3% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 26 | 18 |
